PDS Biotechnology Corporation（纳斯达克代码：PDSB）今日向美国证券交易委员会（SEC）提交的文件显示，公司首席财务官（CFO）、首席财务主管及首席会计主管Lars Boesgaard将于9月12日正式卸任。
这一高层人事变动在SEC文件中得以披露，标志着该公司财务管理层将迎来新的调整期。Boesgaard的离职生效日期恰逢9月中旬，为公司留出了一定的过渡与交接时间。
PDS Biotechnology作为一家专注于免疫疗法研发的生物技术企业，此番核心财务高管更迭备受市场关注。截至目前，公司尚未公布继任者的具体人选或相关过渡安排，外界或将继续关注其后续动向。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.